Share-based Payment Arrangement, Expense of Akero Therapeutics, Inc. from 30 Sep 2018 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Akero Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2018 to 30 Sep 2025.
  • Akero Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $9,261,000, a 24% increase year-over-year.
  • Akero Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $34,276,000, a 20% increase year-over-year.
  • Akero Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $29,698,000, a 38% increase from 2023.
  • Akero Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $21,497,000, a 7.5% decline from 2022.
  • Akero Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $23,243,000, a 131% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Akero Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $34,276,000 $9,261,000 +$1,793,000 +24% 01 Jul 2025 30 Sep 2025 10-Q 07 Nov 2025 2025 Q3
Q2 2025 $32,483,000 $9,055,000 +$1,399,000 +18% 01 Apr 2025 30 Jun 2025 10-Q 08 Aug 2025 2025 Q2
Q1 2025 $31,084,000 $8,784,000 +$1,386,000 +19% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $29,698,000 $7,176,000 +$1,060,000 +17% 01 Oct 2024 31 Dec 2024 10-K 28 Feb 2025 2024 FY
Q3 2024 $28,638,000 $7,468,000 +$1,729,000 +30% 01 Jul 2024 30 Sep 2024 10-Q 07 Nov 2025 2025 Q3
Q2 2024 $26,909,000 $7,656,000 +$2,858,000 +60% 01 Apr 2024 30 Jun 2024 10-Q 08 Aug 2025 2025 Q2
Q1 2024 $24,051,000 $7,398,000 +$2,554,000 +53% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 $21,497,000 $6,116,000 +$2,076,000 +51% 01 Oct 2023 31 Dec 2023 10-K 28 Feb 2025 2024 FY
Q3 2023 $19,421,000 $5,739,000 -$5,992,000 -51% 01 Jul 2023 30 Sep 2023 10-Q 08 Nov 2024 2024 Q3
Q2 2023 $25,413,000 $4,798,000 +$637,000 +15% 01 Apr 2023 30 Jun 2023 10-Q 09 Aug 2024 2024 Q2
Q1 2023 $24,776,000 $4,844,000 +$1,533,000 +46% 01 Jan 2023 31 Mar 2023 10-Q 10 May 2024 2024 Q1
Q4 2022 $23,243,000 $4,040,000 +$1,398,000 +53% 01 Oct 2022 31 Dec 2022 10-K 28 Feb 2025 2024 FY
Q3 2022 $21,845,000 $11,731,000 +$9,119,000 +349% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 $12,726,000 $4,161,000 +$1,725,000 +71% 01 Apr 2022 30 Jun 2022 10-Q 11 Aug 2023 2023 Q2
Q1 2022 $11,001,000 $3,311,000 +$947,000 +40% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q4 2021 $10,054,000 $2,642,000 +$725,000 +38% 01 Oct 2021 31 Dec 2021 10-K 29 Feb 2024 2023 FY
Q3 2021 $9,329,000 $2,612,000 +$1,066,000 +69% 01 Jul 2021 30 Sep 2021 10-Q 04 Nov 2022 2022 Q3
Q2 2021 $8,263,000 $2,436,000 +$1,114,000 +84% 01 Apr 2021 30 Jun 2021 10-Q 05 Aug 2022 2022 Q2
Q1 2021 $7,149,000 $2,364,000 +$1,127,000 +91% 01 Jan 2021 31 Mar 2021 10-Q 06 May 2022 2022 Q1
Q4 2020 $6,022,000 $1,917,000 +$1,247,000 +186% 01 Oct 2020 31 Dec 2020 10-K 25 Feb 2022 2021 FY
Q3 2020 $4,775,000 $1,546,000 +$1,063,000 +220% 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021 2021 Q3
Q2 2020 $3,712,000 $1,322,000 +$920,000 +229% 01 Apr 2020 30 Jun 2020 10-Q 13 Aug 2021 2021 Q2
Q1 2020 $2,792,000 $1,237,000 +$1,022,000 +475% 01 Jan 2020 31 Mar 2020 10-Q 13 May 2021 2021 Q1
Q4 2019 $1,770,000 $670,000 01 Oct 2019 31 Dec 2019 10-K 25 Feb 2022 2021 FY
Q3 2019 $483,000 +$449,000 +1321% 01 Jul 2019 30 Sep 2019 10-Q 12 Nov 2020 2020 Q3
Q2 2019 $402,000 01 Apr 2019 30 Jun 2019 10-Q 12 Aug 2020 2020 Q2
Q1 2019 $215,000 01 Jan 2019 31 Mar 2019 10-Q 13 May 2020 2020 Q1
Q3 2018 $34,000 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019 2019 Q3

Akero Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $29,698,000 +$8,201,000 +38% 01 Jan 2024 31 Dec 2024 10-K 28 Feb 2025 2024 FY
2023 $21,497,000 -$1,746,000 -7.5% 01 Jan 2023 31 Dec 2023 10-K 28 Feb 2025 2024 FY
2022 $23,243,000 +$13,189,000 +131% 01 Jan 2022 31 Dec 2022 10-K 28 Feb 2025 2024 FY
2021 $10,054,000 +$4,032,000 +67% 01 Jan 2021 31 Dec 2021 10-K 29 Feb 2024 2023 FY
2020 $6,022,000 +$4,252,000 +240% 01 Jan 2020 31 Dec 2020 10-K 25 Feb 2022 2021 FY
2019 $1,770,000 +$1,649,000 +1363% 01 Jan 2019 31 Dec 2019 10-K 25 Feb 2022 2021 FY
2018 $121,000 01 Jan 2018 31 Dec 2018 10-K 16 Mar 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.